XTL Biopharmaceuticals (XTLB) Short Interest Ratio & Short Volume

Short interest is the volume of XTL Biopharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 60,200 shares of XTLB short. Learn More on XTL Biopharmaceuticals' current short interest.

XTL Biopharmaceuticals saw a decline in short interest in April. As of April 15th, there was short interest totaling 60,200 shares, a decline of 86.2% from the previous total of 437,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to XTL Biopharmaceuticals: Pieris Pharmaceuticals, Inc. (0.03%), Avalo Therapeutics, Inc. (14.89%), RedHill Biopharma Ltd. (2.51%), Monopar Therapeutics Inc. (2.01%), FSD Pharma Inc. (1.11%), Edesa Biotech, Inc. (0.65%), Kiora Pharmaceuticals, Inc. (0.31%), Purple Biotech Ltd (0.93%), Imunon, Inc. (4.96%), Cocrystal Pharma, Inc. (0.02%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks.

Short selling XTLB is an investing strategy that aims to generate trading profit from XTL Biopharmaceuticals as its price is falling. XTLB shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for XTL Biopharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of XTLB, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including XTLB, twice per month. The most recent reporting period available is April, 15 2024.